CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
22-055

APPROVAL LETTER
NDA 22-055

Glaxo Group Limited d/b/a GlaxoSmithKline
Attention: Debra Hackett
Director, US Regulatory Affairs
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

Dear Ms. Hackett:

Please refer to your new drug application (NDA) dated June 12, 2006, received June 12, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Altabax (retapamulin ointment), 1%.

This new drug application provides for the use of Altabax for the treatment of impetigo.

We acknowledge receipt of your submissions dated July 27, August 10, October 11, 24, and 27, November 1, 6, 16, and 17, and December 12, 2006, and February 2, 12, and 13, March 20, and April 12, 2007.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert, immediate container and carton labels). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling text. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission “FPL for approved NDA 22-055.” Approval of this submission by FDA is not required before the labeling is used.
All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for ages 0 to 2 months and deferring pediatric studies for ages 2 months to 9 months for this application.

Your deferred pediatric study required under section 2 of the Pediatric Research Equity Act (PREA) is considered a required postmarketing study commitment. The status of this postmarketing study shall be reported annually according to 21 CFR 314.81. This commitment is listed below.

1. Deferred pediatric study under PREA for the treatment of impetigo in pediatric patients ages 2 months to 9 months.


Submit final study reports to this NDA. For administrative purposes, all submissions related to this/these pediatric postmarketing study commitment(s) must be clearly designated “Required Pediatric Study Commitments”.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled “Postmarketing Study Commitment Protocol”, “Postmarketing Study Commitment Final Report”, or “Postmarketing Study Commitment Correspondence.”

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Anti-Infective and Ophthalmology Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltville, MD 20705-1266

Please submit one market package of the drug product when it is available.
We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at www.fda.gov/medwatch/report/mmp.htm.

If you have any questions, call Maureen Dillon-Parker, Regulatory Project Manager, at (301)796-0706.

Sincerely,

(See appended electronic signature page)

Edward Cox, M.D., M.P.H.
Office Director (acting)
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure